Although evidence exists concerning the effects of SGLT2-in regarding patients’ CV comorbidity severity stratification, such as the baseline patient stratification as to the presence of ASCVD, heart failure and degrees of renal function decline, it is not sufficient if we want to consider the magnitude of treatment effects, as well as the harm–benefit trade-off, in a more personalized context [84]. Here, SLC5A2 is linked to atherosclerosis.